Form 4: Acrivon Therapeutics Executives Report Tax-Related Stock Dispositions

Acrivon Therapeutics' President and CEO, Peter Blume-Jensen, and EVP, Kristina Masson, reported tax-related dispositions of common stock following restricted stock unit vesting.

Summary

• Peter Blume-Jensen, President and CEO, and Kristina Masson, EVP Business Operations, both Directors of Acrivon Therapeutics, Inc. (ACRV), reported transactions.
• On February 21, 2026, 14,265 shares of Common Stock were disposed of by the Issuer to satisfy mandatory tax withholding requirements upon the vesting of restricted stock units.
• The shares were valued at $1.53 for the purpose of tax withholding.
• Following the reported transaction, Peter Blume-Jensen directly beneficially owns 2,080,204 shares of Common Stock.
• Kristina Masson indirectly beneficially owns 314,127 shares of Common Stock, which are held by her spouse, Peter Blume-Jensen. She disclaims beneficial ownership except to the extent of her pecuniary interest.
• Peter Blume-Jensen indirectly beneficially owns 314,127 shares of Common Stock, which are held by his spouse, Kristina Masson. He disclaims beneficial ownership except to the extent of his pecuniary interest.
• The transaction was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing a routine, non-discretionary transaction related to executive compensation and tax obligations, rather than a strategic sale or a reflection of management's sentiment towards the company's future.

Positives

• The disposition of shares was due to the vesting of restricted stock units, indicating that executive compensation plans are progressing as expected.
• The transaction was executed under a Rule 10b5-1 plan, suggesting a pre-arranged and non-discretionary event.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that routine insider transactions like tax-related dispositions upon restricted stock unit vesting are common practice in executive compensation and are generally not indicative of changes in management's confidence in the company's long-term prospects or operational performance. Such transactions are often pre-scheduled under Rule 10b5-1 plans.

Related Party Transactions

• The filing notes indirect beneficial ownership between spouses, Peter Blume-Jensen and Kristina Masson, where each disclaims beneficial ownership of the other's holdings except to the extent of their pecuniary interest.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction related to executive compensation and tax obligations, not a strategic sale.
• Employees: The vesting of restricted stock units is a standard component of executive compensation, reflecting ongoing employee incentive programs.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary disposition of shares for tax withholding purposes upon the vesting of restricted stock units. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Investors should consider this a standard compensation-related event.

Keywords

Acrivon Therapeutics, ACRV, Form 4, Insider Transaction, Stock Disposition, Restricted Stock Units, Tax Withholding, Peter Blume-Jensen, Kristina Masson